Elutia Inc. (NASDAQ:ELUT) Stock Short Interest Jumps 119.6%

Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 30th, there was short interest totaling 33,661 shares, a growth of 119.6% from the October 15th total of 15,326 shares. Based on an average daily volume of 70,790 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Elutia from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Get Our Latest Report on ELUT

Elutia Price Performance

Elutia stock opened at $0.82 on Monday. The company has a 50 day moving average of $0.82 and a 200-day moving average of $0.97. The company has a quick ratio of 2.61, a current ratio of 2.63 and a debt-to-equity ratio of 0.53. Elutia has a twelve month low of $0.50 and a twelve month high of $1.39. The stock has a market capitalization of $36.32 million, a PE ratio of 0.74 and a beta of 0.93.

Elutia (NASDAQ:ELUT – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.00 million. Elutia had a net margin of 546.70% and a negative return on equity of 140.53%.

About Elutia

(Get Free Report)

Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.

See Also

Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.